Different markers for minimal systemic disease detection in lung cancer patients.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F11%3A33119771" target="_blank" >RIV/61989592:15110/11:33119771 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Different markers for minimal systemic disease detection in lung cancer patients.

Popis výsledku v původním jazyce

Objectives. The role of circulating tumor cells and nucleic acids in prognostication in non-small cell lung cancer patients is controversial, but may be better defined with advancing technologies of detection of such cells or free tumor DNA with higher precision, and improved clinical-pathological correlations. Biomarker measurements of minimal systemic disease (MSD) have the potential to monitor the molecular status of tumors without invasive tumor biopsy at the time of treatment selection. Patients: This is a pilot study to test for the presence of the minimal systemic disease in 69 lung cancer patients undergoing curative surgery. Methods: We used real-time RT-PCR method for absolute gene expression quantification of carcinoembryonic antigen (CEA),epidermal growth factor receptor 1 (EGFR1), palate, lung and nasal epithelium associated protein (LUNX) and hepatocyte growth factor receptor (c-met) in peripheral blood, blood from pulmonary veins and samples of bone marrow. Conclusions:

Název v anglickém jazyce

Different markers for minimal systemic disease detection in lung cancer patients.

Popis výsledku anglicky

Objectives. The role of circulating tumor cells and nucleic acids in prognostication in non-small cell lung cancer patients is controversial, but may be better defined with advancing technologies of detection of such cells or free tumor DNA with higher precision, and improved clinical-pathological correlations. Biomarker measurements of minimal systemic disease (MSD) have the potential to monitor the molecular status of tumors without invasive tumor biopsy at the time of treatment selection. Patients: This is a pilot study to test for the presence of the minimal systemic disease in 69 lung cancer patients undergoing curative surgery. Methods: We used real-time RT-PCR method for absolute gene expression quantification of carcinoembryonic antigen (CEA),epidermal growth factor receptor 1 (EGFR1), palate, lung and nasal epithelium associated protein (LUNX) and hepatocyte growth factor receptor (c-met) in peripheral blood, blood from pulmonary veins and samples of bone marrow. Conclusions:

Druh

O - Ostatní výsledky

CEP obor

FJ - Chirurgie včetně transplantologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NS10285" target="_blank" >NS10285: Význam stanovení minimální reziduální choroby u nemocných s operabilním plicním karcinomem</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů